1![Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to](https://www.pdfsearch.io/img/5a983f00bbfe583a44cfb1c91bed3478.jpg) | Add to Reading ListSource URL: propelopens.com- Date: 2016-07-29 19:00:51
|
---|
2![PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:](https://www.pdfsearch.io/img/43835f4857577fd45f124ec358c07a67.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2016-04-01 12:43:40
|
---|
3![Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL](https://www.pdfsearch.io/img/3fac6c1ef233c6120a5789b7070107d3.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2016-07-08 12:30:12
|
---|
4![Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica](https://www.pdfsearch.io/img/7040f7369c55cff4cb155ccfbcfdba74.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2016-06-01 10:43:20
|
---|
5![Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp](https://www.pdfsearch.io/img/47e02d91e9c60353ada1d287d912e88d.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2015-11-17 11:28:47
|
---|
6![Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants Savings Associated with Reduced Post-Operative Interventions Support Use of PROPEL MENLO PARK, Calif., Novembe Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants Savings Associated with Reduced Post-Operative Interventions Support Use of PROPEL MENLO PARK, Calif., Novembe](https://www.pdfsearch.io/img/f7d29d867333bfd5582a4d7556f4341b.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2015-11-10 10:16:52
|
---|
7![Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials Statement Supports Use of PROPEL, the Only FDA-Approved Biomaterial Used to Improve Patient Outcomes in Sinus Procedures Menlo Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials Statement Supports Use of PROPEL, the Only FDA-Approved Biomaterial Used to Improve Patient Outcomes in Sinus Procedures Menlo](https://www.pdfsearch.io/img/fb3b30dc786710191e5b72b24f30ebe1.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2015-10-21 16:28:17
|
---|
8![Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect](https://www.pdfsearch.io/img/e81b319e68080cf39181d186e0079488.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2016-02-02 07:14:47
|
---|
9![Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant PROPEL Mini Now Indicated to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—March 23, 2016—Intersect ENT, In Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant PROPEL Mini Now Indicated to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—March 23, 2016—Intersect ENT, In](https://www.pdfsearch.io/img/38483115c7160ec9622e9d2ee7395779.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English - Date: 2016-03-23 16:11:00
|
---|
10![Intersect ENT Appoints David Lehman General Counsel MENLO PARK, Calif., February 22, 2016 – Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat Intersect ENT Appoints David Lehman General Counsel MENLO PARK, Calif., February 22, 2016 – Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat](https://www.pdfsearch.io/img/55394ff27e4fbc245071ff32f51a73b7.jpg) | Add to Reading ListSource URL: propelopens.comLanguage: English |
---|